Galapagos NV (NASDAQ:GLPG) Given Consensus Recommendation of “Reduce” by Analysts

Galapagos NV (NASDAQ:GLPG) has received a consensus rating of “Reduce” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $25.33.

Several brokerages have recently commented on GLPG. Morgan Stanley lowered shares of Galapagos from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $31.00 to $22.00 in a research note on Friday, February 14th. Barclays reissued an “underweight” rating on shares of Galapagos in a research report on Thursday, January 23rd. Finally, TD Cowen cut Galapagos from a “strong-buy” rating to a “strong sell” rating in a research report on Thursday, January 9th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of GLPG. R Squared Ltd bought a new stake in Galapagos during the fourth quarter valued at about $26,000. GAMMA Investing LLC lifted its position in shares of Galapagos by 77.4% during the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 974 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Galapagos by 45.9% during the 4th quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company’s stock valued at $247,000 after purchasing an additional 2,824 shares during the period. QRG Capital Management Inc. grew its holdings in Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 1,866 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC bought a new position in Galapagos in the 4th quarter worth approximately $311,000. Institutional investors own 32.46% of the company’s stock.

Galapagos Price Performance

Shares of NASDAQ GLPG opened at $25.46 on Friday. The business has a 50 day simple moving average of $25.07 and a 200 day simple moving average of $26.94. Galapagos has a 52 week low of $22.36 and a 52 week high of $32.57.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.